Annexon, Inc. ANNX

BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9,

In August 2026, Annexon reported a higher second-quarter net loss of US$55.35 million but a lower year-to-date loss of US$99.49 million, while updating investors on its ongoing Phase 3 ARCHER II trial and new open-label extension study for vonaprument in geographic atrophy. A distinctive aspect of this update is Annexon’s dual primary endpoint design at Months 15 and 24 for ARCHER II, paired with vonaprument’s FDA Fast Track and EMA PRIME designations, which together clarify a globally...